JP2021501805A5 - - Google Patents

Info

Publication number
JP2021501805A5
JP2021501805A5 JP2020544334A JP2020544334A JP2021501805A5 JP 2021501805 A5 JP2021501805 A5 JP 2021501805A5 JP 2020544334 A JP2020544334 A JP 2020544334A JP 2020544334 A JP2020544334 A JP 2020544334A JP 2021501805 A5 JP2021501805 A5 JP 2021501805A5
Authority
JP
Japan
Prior art keywords
cyclopropyl
vinyl
isoxazole
carboxylic acid
azabicyclo
Prior art date
Application number
JP2020544334A
Other languages
English (en)
Japanese (ja)
Other versions
JP7264906B2 (ja
JP2021501805A (ja
JPWO2019089670A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/058323 external-priority patent/WO2019089670A1/en
Publication of JP2021501805A publication Critical patent/JP2021501805A/ja
Publication of JP2021501805A5 publication Critical patent/JP2021501805A5/ja
Publication of JPWO2019089670A5 publication Critical patent/JPWO2019089670A5/ja
Application granted granted Critical
Publication of JP7264906B2 publication Critical patent/JP7264906B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020544334A 2017-11-01 2018-10-31 ファルネソイドx受容体モジュレーターとしてのアルケン化合物 Active JP7264906B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762580060P 2017-11-01 2017-11-01
US62/580,060 2017-11-01
PCT/US2018/058323 WO2019089670A1 (en) 2017-11-01 2018-10-31 Alkene compounds as farnesoid x receptor modulators

Publications (4)

Publication Number Publication Date
JP2021501805A JP2021501805A (ja) 2021-01-21
JP2021501805A5 true JP2021501805A5 (https=) 2022-03-18
JPWO2019089670A5 JPWO2019089670A5 (https=) 2022-03-18
JP7264906B2 JP7264906B2 (ja) 2023-04-25

Family

ID=64332184

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020544334A Active JP7264906B2 (ja) 2017-11-01 2018-10-31 ファルネソイドx受容体モジュレーターとしてのアルケン化合物

Country Status (7)

Country Link
US (1) US11168079B2 (https=)
EP (1) EP3704106B1 (https=)
JP (1) JP7264906B2 (https=)
KR (1) KR102732404B1 (https=)
CN (1) CN111511731B (https=)
ES (1) ES2944657T3 (https=)
WO (1) WO2019089670A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110128432B (zh) 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
WO2020243423A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
KR20220030222A (ko) 2019-05-31 2022-03-10 이케나 온콜로지, 인코포레이티드 Tead 억제제 및 이의 용도
AU2020336272A1 (en) 2019-08-23 2022-04-14 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CN114375193B (zh) 2019-09-12 2024-05-14 拓臻制药公司 甲状腺激素受体β激动剂化合物
IL293892A (en) 2020-01-15 2022-08-01 Inserm Institut National De La Sant? Et De La Rech M?Dicale Use of fxr agonists for treating an infection by hepatitis d virus
EP4211139A4 (en) 2020-09-10 2024-12-18 Gasherbrum Bio, Inc. HETEROCYCLIC GLP-1 AGONISTS
JP2024502673A (ja) 2021-01-14 2024-01-22 ウエヌイグレックオ・ファーマ Hbv感染の処置のためのfxrアゴニストとifnの相乗効果
JP2024517181A (ja) 2021-04-28 2024-04-19 ウエヌイグレックオ・ファーマ 組合せ治療としてfxrアゴニストを使用するtlr3アゴニストの効果の強い増強
WO2023220404A1 (en) * 2022-05-13 2023-11-16 Terns Pharmaceuticals, Inc. Treatment of non-alcoholic steatohepatitis
US20240398794A1 (en) 2023-04-07 2024-12-05 Terns Pharmaceuticals, Inc. COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOF

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993013101A1 (fr) 1991-12-27 1993-07-08 Yoshitomi Pharmaceutical Industries, Ltd. Compose de pyridonecarboxylate, son utilisation pharmaceutique et compose spiro
WO1998017276A1 (en) 1996-10-25 1998-04-30 Merck & Co., Inc. Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists
DE69940958D1 (de) 1998-12-23 2009-07-16 Glaxo Group Ltd Bestimmungsmethode fur liganden der nuklearen rezeptoren
ATE381542T1 (de) 2001-08-13 2008-01-15 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
WO2004048349A1 (en) 2002-11-22 2004-06-10 Smithkline Beecham Corporation Farnesoid x receptor agonists
WO2006006490A1 (ja) 2004-07-08 2006-01-19 Ono Pharmaceutical Co., Ltd. スピロ化合物
WO2007076260A2 (en) 2005-12-19 2007-07-05 Smithkline Beecham Corporation Farnesoid x receptor agonists
CA2640476A1 (en) 2006-02-03 2007-08-16 Eli Lilly And Company Compounds and methods for modulating fx-receptors
TW200812982A (en) 2006-05-24 2008-03-16 Lilly Co Eli Compounds and methods for modulating FXR
CN101448791B (zh) 2006-05-24 2011-11-16 伊莱利利公司 Fxr激动剂
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
CL2007003035A1 (es) 2006-10-24 2008-05-16 Smithkline Beechman Corp Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
EP2108017A2 (en) 2007-01-30 2009-10-14 Biogen Idec MA, Inc. Imidazolone compounds as tgf-beta family type i receptors, alk5 and/or alk4 antagonists
KR20100038102A (ko) 2007-06-13 2010-04-12 글락소스미스클라인 엘엘씨 파네소이드 x 수용체 작용제
MX2009013946A (es) 2007-07-02 2010-03-10 Glaxosmithkline Llc Agonistas del receptor de farnesoide x.
WO2009009059A1 (en) 2007-07-09 2009-01-15 Biogen Idec Ma Inc. Spiro compounds as antagonists of tgf-beta
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
CN101910151A (zh) 2007-10-22 2010-12-08 先灵公司 双环杂环衍生物及其作为gpr119活性调节剂的用途
EP2128158A1 (en) 2008-05-26 2009-12-02 Phenex Pharmaceuticals AG Heterocyclic cyclopropyl-substituted FXR binding compounds
US20110230493A1 (en) 2008-11-21 2011-09-22 Pfizer Inc. 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US8440710B2 (en) 2009-10-15 2013-05-14 Hoffmann-La Roche Inc. HSL inhibitors useful in the treatment of diabetes
WO2012087521A1 (en) 2010-12-20 2012-06-28 Irm Llc Compositions and methods for modulating farnesoid x receptors
EP2655368A1 (en) * 2010-12-20 2013-10-30 Irm Llc Compositions and methods for modulating farnesoid x receptors
CU24152B1 (es) * 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
IN2014DN09346A (https=) 2012-06-13 2015-07-17 Hoffmann La Roche
EP2903985A1 (en) 2012-10-03 2015-08-12 Advinus Therapeutics Limited Spirocyclic compounds, compositions and medicinal applications thereof
EP3034501A1 (en) * 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy containing FXR (NR1H4) modulating compounds
EP3034499A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
MX2017008057A (es) 2014-12-18 2017-09-28 Novartis Ag Derivados de azabiciclooctano como agonistas de fxr para el uso en el tratamiento de enfermedades hepaticas y gastrointestinales.
CN106146483A (zh) 2015-04-23 2016-11-23 上海迪诺医药科技有限公司 杂环类法尼酯衍生物x受体调节剂
CN106946867B (zh) * 2016-01-06 2019-11-12 广州市恒诺康医药科技有限公司 Fxr受体调节剂及其制备方法和用途
WO2017133521A1 (zh) 2016-02-01 2017-08-10 山东轩竹医药科技有限公司 Fxr受体激动剂
CN107021958A (zh) 2016-02-01 2017-08-08 山东轩竹医药科技有限公司 Fxr受体激动剂
MX384205B (es) 2016-02-22 2025-03-14 Novartis Ag Metodos para usar agonistas de fxr.
ES2862194T3 (es) 2016-02-22 2021-10-07 Novartis Ag Métodos para usar agonistas del FXR
US10080741B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017189663A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017189651A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017201155A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
MX385718B (es) 2016-06-13 2025-03-18 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4).
AR108711A1 (es) 2016-06-13 2018-09-19 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4)
CN108430998B (zh) 2016-09-28 2021-07-09 四川科伦博泰生物医药股份有限公司 氮杂双环衍生物及其制备方法和用途
CN106632294A (zh) 2016-12-15 2017-05-10 宁波百纳西药业有限公司 一种螺环化合物及其药物用途

Similar Documents

Publication Publication Date Title
JP2021501805A5 (https=)
JP2021501218A5 (https=)
JP2021501220A5 (https=)
RU2017105296A (ru) Новые соединения
JP2020514267A5 (https=)
JP2021528467A5 (https=)
TWI494314B (zh) 5,7-取代的-咪唑并[1,2-c]嘧啶
JP2017530960A5 (https=)
ES2898965T3 (es) Sondas de formación de imágenes de la proteína Huntingtina
JP2021501806A5 (https=)
JP2016507551A5 (https=)
HRP20160539T1 (hr) Antagonisti trpv4
JP5864589B2 (ja) 細菌トポイソメラーゼii阻害性2−エチルカルバモイルアミノ−1,3−ベンゾチアゾール−5−イル類
JPWO2020005873A5 (https=)
RU2015129538A (ru) Замещенные имидазопиридины в качестве ингибиторов hdm2
WO2018218133A1 (en) Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
EA016028B1 (ru) Конденсированные гетероциклические производные и их применение
JP2020514267A (ja) Malt1阻害剤としてのピラゾール誘導体
ME02330B (me) Derivati 2,3-dihidro-1h-inden-1-il-2,7-diazaspir0[3.6]nonana i njihova upotreba kao antagonista ili inverznih agonista grelinskog receptora
JP2018522046A5 (https=)
JP2013523884A5 (https=)
AU2016222468A1 (en) SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS
JP2014518214A5 (https=)
JP2014530238A5 (https=)
JP2016514719A5 (https=)